{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:32Z","timestamp":1792807472036,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00284-022-02875-9","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T10:07:43Z","timestamp":1651313263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Panorama of Bacterial Infections Caused by Epidemic Resistant Strains"],"prefix":"10.1007","volume":"79","author":[{"given":"Jo\u00e3o Victor","family":"de Oliveira Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio Dias","family":"da Costa J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrelli Meridiana","family":"de F\u00e1tima Ramos dos Santos Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago Dillion Lima","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Barbosa","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi Lacerda","family":"Coriolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Roberto Cirilo","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena Menezes Estevam","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-3502","authenticated-orcid":false,"given":"Isabella Mac\u00e1rio Ferro","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"1","key":"2875_CR1","first-page":"135","volume":"90","author":"M Lobanovska","year":"2017","unstructured":"Lobanovska M, Pilla G (2017) Focus: drug development: Penicillin\u2019s discovery and antibiotic resistance: lessons for the future? Yale J Biol Med 90(1):135","journal-title":"Yale J Biol Med"},{"issue":"9","key":"2875_CR2","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1128\/jcm.33.9.2400-2404.1995","volume":"33","author":"LA Teixeira","year":"1995","unstructured":"Teixeira LA et al (1995) Geographic spread of epidemic multiresistant Staphylococcus aureus clone in Brazil. J Clin Microbiol 33(9):2400\u20132404","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2875_CR3","doi-asserted-by":"publisher","first-page":"e00088","DOI":"10.1128\/CMR.00088-17","volume":"31","author":"SR Partridge","year":"2018","unstructured":"Partridge SR et al (2018) Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev 31(4):e00088-e117","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2875_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/medicina47030019","volume":"47","author":"A Giedraitien\u0117","year":"2011","unstructured":"Giedraitien\u0117 A et al (2011) Antibiotic resistance mechanisms of clinically important bacteria. Medicina 47(3):19","journal-title":"Medicina"},{"issue":"7","key":"2875_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/pathogens9070522","volume":"9","author":"A Fodor","year":"2020","unstructured":"Fodor A et al (2020) Multidrug Resistance (MDR) and collateral sensitivity in bacteria, with special attention to genetic and evolutionary aspects and to the perspectives of antimicrobial peptides\u2014a review. Pathogens 9(7):522","journal-title":"Pathogens"},{"issue":"3","key":"2875_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"2875_CR7","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1128\/AAC.01464-06","volume":"51","author":"F Perez","year":"2007","unstructured":"Perez F et al (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51(10):3471\u20133484","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2875_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2471\/BLT.11.088815","volume":"89","author":"H Kelly","year":"2011","unstructured":"Kelly H (2011) The classical definition of a pandemic is not elusive. Bull World Health Org 89(1):540\u2013541","journal-title":"Bull World Health Org"},{"key":"2875_CR9","unstructured":"World Health Organization (WHO). Global action plan on antimicrobial resistance, 2015. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA68\/A68_ACONF1Rev1-en.pdf. Accessed 21 Apr 2020"},{"issue":"7499","key":"2875_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/509141a","volume":"509","author":"S Reardon","year":"2021","unstructured":"Reardon S (2021) Antibiotic resistance sweeping developing world. Nat News 509(7499):141","journal-title":"Nat News"},{"key":"2875_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jiph.2021.02.011","volume":"14","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Bornman C, Zafer MM (2021) Antimicrobial resistance threats in the emerging COVID-19 pandemic: where do we stand? J Infect Public Health 14:555\u2013560","journal-title":"J Infect Public Health"},{"issue":"2","key":"2875_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v11020116","volume":"11","author":"ME Nickol","year":"2019","unstructured":"Nickol ME et al (2019) Characterization of host and bacterial contributions to lung barrier dysfunction following co-infection with 2009 pandemic influenza and methicillin resistant Staphylococcus aureus. Viruses 11(2):1\u201318","journal-title":"Viruses"},{"issue":"1","key":"2875_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-017-1801-3","volume":"21","author":"A Hassoun","year":"2017","unstructured":"Hassoun A, Linden PK, Friedman B (2017) Incidence, prevalence, and management of MRSA bacteremia across patient populations\u2014a review of recent developments in MRSA management and treatment. Crit Care 21(1):1\u201310","journal-title":"Crit Care"},{"issue":"9","key":"2875_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","volume":"68","author":"AP Kourtis","year":"2019","unstructured":"Kourtis AP et al (2019) Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States. Morb Mortal Wkly Rep 68(9):214\u2013219","journal-title":"Morb Mortal Wkly Rep"},{"issue":"2","key":"2875_CR15","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, Deleo FR (2017) Focus: infectious diseases: vancomycin resistance in Staphylococcus aureus. Yale J Biol Med 90(2):269","journal-title":"Yale J Biol Med"},{"issue":"1","key":"2875_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/ddt.2016.01080","volume":"11","author":"S Panthee","year":"2017","unstructured":"Panthee S et al (2017) Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates. Drug Discov Therapeut 11(1):1\u20136","journal-title":"Drug Discov Therapeut"},{"key":"2875_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","volume":"21","author":"Y Cong","year":"2020","unstructured":"Cong Y, Yang S, Rao X (2020) Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features. J Adv Res 21:169\u2013176","journal-title":"J Adv Res"},{"issue":"2","key":"2875_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3201\/eid2402.171074","volume":"24","author":"K Becker","year":"2018","unstructured":"Becker K et al (2018) Plasmid-encoded transferable mecB-mediated methicillin resistance in Staphylococcus aureus. Emerg Infect Dis 24(2):242\u2013252","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2875_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.vetmic.2013.12.024","volume":"171","author":"E Van Duijkeren","year":"2014","unstructured":"Van Duijkeren E et al (2014) Prevalence of methicillin-resistant Staphylococcus aureus carrying mecA or mecC in dairy cattle. Vet Microbiol 171(1):364\u2013367","journal-title":"Vet Microbiol"},{"issue":"4","key":"2875_CR20","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1128\/CMR.00020-18","volume":"31","author":"S Lakhundi","year":"2018","unstructured":"Lakhundi S, Zhang K (2018) Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev 31(4):e00020-e118","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2875_CR21","first-page":"1","volume":"2020","author":"J Junnila","year":"2020","unstructured":"Junnila J et al (2020) Changing epidemiology of methicillin-resistant Staphylococcus aureus in a low endemicity area\u2014new challenges for MRSA control. Eur J Clin Microbiol Infect Dis 2020(1):1\u20139","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"13","key":"2875_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2019.24.13.1800124","volume":"24","author":"S Packer","year":"2019","unstructured":"Packer S et al (2019) Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. Eurosurveillance 24(13):1\u201310","journal-title":"Eurosurveillance"},{"issue":"3","key":"2875_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1099\/jmm.0.000687","volume":"67","author":"S Osaka","year":"2018","unstructured":"Osaka S et al (2018) Genetic shifts in methicillin-resistant Staphylococcus aureus epidemic clones and toxin gene profiles in Japan: comparative analysis among pre-epidemic, epidemic and post-epidemic phases. J Med Microbiol 67(3):392\u2013399","journal-title":"J Med Microbiol"},{"issue":"2","key":"2875_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S095026881400065X","volume":"143","author":"B Dhawan","year":"2015","unstructured":"Dhawan B et al (2015) Dissemination of methicillin-resistant Staphylococcus aureus SCCmec type IV and SCCmec type V epidemic clones in a tertiary hospital: challenge to infection control. Epidemiol Infect 143(2):343\u2013353","journal-title":"Epidemiol Infect"},{"issue":"7","key":"2875_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jiac.2018.03.004","volume":"24","author":"D Harada","year":"2018","unstructured":"Harada D et al (2018) Change in genotype of methicillin-resistant Staphylococcus aureus (MRSA) affects the antibiogram of hospital-acquired MRSA. J Infect Chemother 24(7):563\u2013569","journal-title":"J Infect Chemother"},{"issue":"7","key":"2875_CR26","first-page":"861","volume":"37","author":"YM Zhong","year":"2017","unstructured":"Zhong YM et al (2017) Emergence of methicillin-resistant Staphylococcus aureus SCCmec type IV\/V epidemic clones in a large teaching hospital in China. J S Med Univ 37(7):861\u2013865","journal-title":"J S Med Univ"},{"issue":"2","key":"2875_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bjid.2019.04.005","volume":"23","author":"SPD Carvalho","year":"2019","unstructured":"Carvalho SPD et al (2019) Molecular characteristics of methicillin-resistant Staphylococcus aureus isolates from hospital and community environments in northeastern Brazil. Braz J Infect Dis 23(2):134\u2013138","journal-title":"Braz J Infect Dis"},{"issue":"2","key":"2875_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/mdr.2018.0046","volume":"25","author":"JL Pereira","year":"2019","unstructured":"Pereira JL et al (2019) Antimicrobial resistance and molecular characterization of extended-spectrum \u03b2-lactamases of Escherichia coli and Klebsiella spp. isolates from urinary tract infections in Southern Brazil. Microbial Drug Resist 25(2):173\u2013181","journal-title":"Microbial Drug Resist"},{"issue":"4","key":"2875_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2017.04.016","volume":"88","author":"IA Tickler","year":"2017","unstructured":"Tickler IA et al (2017) Continued expansion of USA300-like methicillin-resistant Staphylococcus aureus (MRSA) among hospitalized patients in the United States. Diagn Microbiol Infect Dis 88(4):342\u2013347","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"2875_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/antibiotics9110762","volume":"9","author":"T Morrisette","year":"2020","unstructured":"Morrisette T et al (2020) The evolving reduction of vancomycin and daptomycin susceptibility in MRSA\u2014salvaging the gold standards with combination therapy. Antibiotics 9(11):762\u2013783","journal-title":"Antibiotics"},{"issue":"5","key":"2875_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/14656566.2018.1442826","volume":"19","author":"A Khan","year":"2018","unstructured":"Khan A et al (2018) Current and future treatment options for community-associated MRSA infection. Expert Opin Pharmacother 19(5):457\u2013470","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2875_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1128\/AAC.00829-20","volume":"64","author":"KV Ovchinnikov","year":"2020","unstructured":"Ovchinnikov KV et al (2020) Successful development of bacteriocins into therapeutic formulation for treatment of MRSA skin infection in a murine model. Antimicrob Agents Chemother 64(12):829\u2013920","journal-title":"Antimicrob Agents Chemother"},{"key":"2875_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijscr.2018.08.038","volume":"52","author":"N Okada","year":"2018","unstructured":"Okada N et al (2018) A case report of postoperative VRSA enteritis: effective management of rifampicin for vancomycin resistant Staphylococcus aureus enteritis after esophagectomy and colon reconstruction. Int J Surg Case Rep 52:75\u201378","journal-title":"Int J Surg Case Rep"},{"key":"2875_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jsat.2018.11.014","volume":"98","author":"MD Godley","year":"2019","unstructured":"Godley MD et al (2019) A randomized trial of volunteer recovery support for adolescents (VRSA) following residential treatment discharge. J Subst Abuse Treatm 98:15\u201325","journal-title":"J Subst Abuse Treatm"},{"issue":"1","key":"2875_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-019-0594-3","volume":"8","author":"R Markwart","year":"2019","unstructured":"Markwart R et al (2019) The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control 8(1):1\u201311","journal-title":"Antimicrob Resist Infect Control"},{"key":"2875_CR36","first-page":"217","volume":"8","author":"T O\u2019Driscoll","year":"2015","unstructured":"O\u2019Driscoll T, Crank CW (2015) Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 8:217","journal-title":"Infect Drug Resist"},{"key":"2875_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jgar.2020.12.005","volume":"24","author":"BA L\u00f3pez-Luis","year":"2021","unstructured":"L\u00f3pez-Luis BA et al (2021) Risk factors and outcomes associated with vancomycin-resistant Enterococcus faecium and ampicillin-resistant Enterococcus faecalis bacteraemia: a 10-year study in a tertiary-care centre in Mexico City. J Glob Antimicrob Resist 24:198\u2013204","journal-title":"J Glob Antimicrob Resist"},{"key":"2875_CR38","first-page":"7","volume":"5","author":"C Gorrie","year":"2019","unstructured":"Gorrie C et al (2019) Genomics of vancomycin-resistant Enterococcus faecium. Microb Genom 5:7","journal-title":"Microb Genom"},{"issue":"10","key":"2875_CR39","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/JCM.00211-16","volume":"54","author":"ML Faron","year":"2016","unstructured":"Faron ML, Ledeboer NA, Buchan BW (2016) Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant Enterococcus in the health care setting. J Clin Microbiol 54(10):2436\u20132447","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2875_CR40","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/mdr.2017.0147","volume":"24","author":"MO Ahmed","year":"2018","unstructured":"Ahmed MO, Baptiste KE (2018) Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health. Microb Drug Resist 24(5):590\u2013606","journal-title":"Microb Drug Resist"},{"issue":"4","key":"2875_CR41","first-page":"323","volume":"9","author":"HS Kafil","year":"2014","unstructured":"Kafil HS, Asgharzadeh M (2014) Vancomycin-resistant enteroccus faecium and enterococcus faecalis isolated from education hospital of iran. Maedica 9(4):323","journal-title":"Maedica"},{"issue":"1","key":"2875_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.41.1.24","volume":"41","author":"C Poyart","year":"1997","unstructured":"Poyart C et al (1997) Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 41(1):24\u201329","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2875_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1086\/321815","volume":"33","author":"GM Eliopoulos","year":"2001","unstructured":"Eliopoulos GM, Gold HS (2001) Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 33(2):210\u2013219","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2875_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1128\/CMR.13.4.686","volume":"13","author":"Y Cetinkaya","year":"2000","unstructured":"Cetinkaya Y, Falk P, Mayhall CG (2000) Vancomycin-resistant enterococci. Clin Microbiol Rev 13(4):686\u2013707","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2875_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1586\/14787210.2015.1001839","volume":"13","author":"KE Barber","year":"2015","unstructured":"Barber KE et al (2015) Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther 13(3):363\u2013377","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"2875_CR46","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM et al (2016) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014. Infect Control Hosp Epidemiol 37(11):1288\u20131301","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"2875_CR47","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/mdr.2020.0171","volume":"27","author":"N Riccardi","year":"2021","unstructured":"Riccardi N et al (2021) Therapeutic options for infections due to vanB genotype vancomycin-resistant Enterococci. Microb Drug Resist 27(4):536\u2013545","journal-title":"Microb Drug Resist"},{"issue":"8","key":"2875_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26633\/RPSP.2017.9","volume":"41","author":"M Marques","year":"2017","unstructured":"Marques M et al (2017) Antituberculosis-drug resistance in the border of Brazil with Paraguay and Bolivia\/Resistencia as drogas antituberculose na fronteira do Brasil com Paraguai e Bolivia. Rev Panam Salud Publ 41(8):1","journal-title":"Rev Panam Salud Publ"},{"issue":"4","key":"2875_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.6026\/97320630015261","volume":"15","author":"A Prasanna","year":"2019","unstructured":"Prasanna A, Niranjan V (2019) Classification of Mycobacterium tuberculosis DR, MDR, XDR isolates and identification of signature mutationpattern of drug resistance. Bioinformation 15(4):261","journal-title":"Bioinformation"},{"key":"2875_CR50","unstructured":"WHO \u2013 World Health Organization. Tuberculose. 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Accessed 13 May 2020."},{"key":"2875_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcimb.2018.00114","volume":"8","author":"HM Hameed","year":"2018","unstructured":"Hameed HM et al (2018) Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. Front Cell Infect Microbiol 8:114","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"2875_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antibiotics3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino JC, Martin A (2014) Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3(3):317\u2013340","journal-title":"Antibiotics"},{"key":"2875_CR53","unstructured":"WHO \u2013 World Health Organization. Global Tuberculosis Report 2019. World Health Organization: Geneva, Switzerland, 2019."},{"issue":"6","key":"2875_CR54","doi-asserted-by":"publisher","first-page":"s37","DOI":"10.7861\/clinmedicine.15-6-s37","volume":"15","author":"K Kumar","year":"2015","unstructured":"Kumar K, Abubakar I (2015) Clinical implications of the global multidrug-resistant tuberculosis epidemic. Clin Med 15(6):s37-42","journal-title":"Clin Med"},{"issue":"6","key":"2875_CR55","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/app10062153","volume":"10","author":"A Iacobino","year":"2020","unstructured":"Iacobino A, Fattorini L, Giannoni F (2020) Drug-resistant tuberculosis 2020: where we stand. Appl Sci 10(6):2153","journal-title":"Appl Sci"},{"issue":"2","key":"2875_CR56","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20200027","volume":"46","author":"DR Silva","year":"2020","unstructured":"Silva DR, Mello FCQ, Migliori GB (2020) Tuberculosis series 2020. J Bras Pneumol 46(2):e20200027","journal-title":"J Bras Pneumol"},{"issue":"2","key":"2875_CR57","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20200009","volume":"46","author":"DR Silva","year":"2020","unstructured":"Silva DR, Mello FCQ, Migliori GB (2020) Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol 46(2):e20200009","journal-title":"J Bras Pneumol"},{"issue":"10","key":"2875_CR58","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P et al (2019) Treatment of drug-resistant tuberculosis: An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 200(10):e93\u2013e142","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2875_CR59","first-page":"303","volume":"7","author":"SK Sah","year":"2015","unstructured":"Sah SK, Hemalatha S (2015) Extended spectrum Beta lactamase (ESBL) Mechanism of antibiotic resistance and Epidemiology. Int J Pharm Res 7(2):303\u2013309","journal-title":"Int J Pharm Res"},{"issue":"5","key":"2875_CR60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/fmb.15.16","volume":"10","author":"R Tal Jasper","year":"2015","unstructured":"Tal Jasper R et al (2015) The complex epidemiology of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae. Future Microbiol 10(5):819\u2013839","journal-title":"Future Microbiol"},{"key":"2875_CR61","unstructured":"CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019."},{"key":"2875_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/82_2018_109","volume-title":"Escherichia coli, a Versatile Pathogen","author":"Y Yair","year":"2018","unstructured":"Yair Y, Gophna U (2018) Pandemic Bacteremic Escherichia coli Strains: evolution and emergence of drug-resistant pathogens. Escherichia coli, a Versatile Pathogen. Springer, Cham, pp 163\u2013180"},{"issue":"1","key":"2875_CR63","first-page":"24555","volume":"4","author":"A Brolund","year":"2014","unstructured":"Brolund A (2014) Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect Ecol Epidemiol 4(1):24555","journal-title":"Infect Ecol Epidemiol"},{"issue":"7","key":"2875_CR64","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.meegid.2011.06.001","volume":"11","author":"Y Chong","year":"2011","unstructured":"Chong Y, Ito Y, Kamimura T (2011) Genetic evolution and clinical impact in extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol 11(7):1499\u20131504","journal-title":"Infect Genet Evol"},{"issue":"1","key":"2875_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12879-019-4387-3","volume":"19","author":"V Gupta","year":"2019","unstructured":"Gupta V et al (2019) Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013\u20132017. BMC Infect Dis 19(1):742","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2875_CR66","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jgar.2015.05.005","volume":"3","author":"SH Lob","year":"2015","unstructured":"Lob SH et al (2015) Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011\u20132013. J Glob Antimicrob Resist 3(3):190\u2013197","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"2875_CR67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jac\/dkw398","volume":"72","author":"SS Jean","year":"2016","unstructured":"Jean SS, Hsueh PR (2016) Distribution of ESBLs, AmpC \u03b2-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008\u201314: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 72(1):166\u2013171","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2875_CR68","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijantimicag.2009.05.011","volume":"34","author":"H Iabadene","year":"2009","unstructured":"Iabadene H et al (2009) Prevalence of plasmid-mediated AmpC \u03b2-lactamases among Enterobacteriaceae in Algiers hospitals. Int J Antimicrob Agents 34(4):340\u2013342","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2875_CR69","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijantimicag.2011.04.012","volume":"38","author":"T Naas","year":"2011","unstructured":"Naas T et al (2011) Outbreak of Salmonella enterica serotype Infantis producing ArmA 16S RNA methylase and CTX-M-15 extended-spectrum \u03b2-lactamase in a neonatology ward in Constantine, Algeria. Int J Antimicrob Agents 38(2):135\u2013139","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2875_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14787210.2018.1436966","volume":"16","author":"C Sheu","year":"2018","unstructured":"Sheu C et al (2018) Management of infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: current evidence and future prospects. Expert Rev Anti Infect Ther 16(3):205\u2013218","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2875_CR71","doi-asserted-by":"crossref","unstructured":"Tamma PD et al. Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical Infectious Diseases 2021.","DOI":"10.1093\/cid\/ciab1013"},{"issue":"4","key":"2875_CR72","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","volume":"45","author":"H Yigit","year":"2001","unstructured":"Yigit H et al (2001) Novel carbapenem-hydrolyzing-lactamase, KPC-1, from a carbapenem resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45(4):1151\u20131161","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2875_CR73","first-page":"16","volume":"6","author":"LS Andrade","year":"2017","unstructured":"Andrade LS, Darini ALC (2017) Bacilos gram-negativos produtores de beta-lactamases: que bla bla bla \u00e9 esse? J Infect Control 6(1):16\u201325","journal-title":"J Infect Control"},{"issue":"4","key":"2875_CR74","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhin.2020.01.005","volume":"104","author":"AJ Mathers","year":"2020","unstructured":"Mathers AJ et al (2020) Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species. J Hosp Infect 104(4):456\u2013458","journal-title":"J Hosp Infect"},{"issue":"1","key":"2875_CR75","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1128\/AAC.00736-08","volume":"53","author":"J Monteiro","year":"2009","unstructured":"Monteiro J et al (2009) First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 53(1):333\u2013334","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2875_CR76","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/jac\/36.3.585","volume":"36","author":"W Scaife","year":"1995","unstructured":"Scaife W et al (1995) Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother 36(3):585\u2013586","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2875_CR77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/AAC.35.1.147","volume":"35","author":"M Watanabe","year":"1991","unstructured":"Watanabe M et al (1991) Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35(1):147\u2013151","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2875_CR78","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1128\/AAC.00186-06","volume":"50","author":"MV Villegas","year":"2006","unstructured":"Villegas MV et al (2006) First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 50(8):2880\u20132882","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2875_CR79","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1128\/AAC.01019-15","volume":"59","author":"JDD Pitout","year":"2015","unstructured":"Pitout JDD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59(10):5873\u20135884","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2875_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-018-0435-9","volume":"7","author":"W Zhang","year":"2018","unstructured":"Zhang W et al (2018) In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control 7(1):1\u20139","journal-title":"Antimicrob Resist Infect Control"},{"issue":"16","key":"2875_CR81","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2217\/fmb-2021-0007","volume":"16","author":"F Romanelli","year":"2021","unstructured":"Romanelli F et al (2021) Meropenem\/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment. Future Microbiol 16(16):1261\u20131266","journal-title":"Future Microbiol"},{"issue":"3","key":"2875_CR82","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1128\/AAC.02123-13","volume":"58","author":"X Wang","year":"2014","unstructured":"Wang X et al (2014) In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 58(3):1774\u20131778","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2875_CR83","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00203-020-02161-x","volume":"203","author":"B Bedeni\u0107","year":"2021","unstructured":"Bedeni\u0107 B et al (2021) Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates. Arch Microbiol 203(4):1825\u20131831","journal-title":"Arch Microbiol"},{"key":"2875_CR84","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3855\/jidc.9501","volume":"11","author":"M Shaaban","year":"2018","unstructured":"Shaaban M et al (2018) Molecular characterization of resistance mechanisms in Pseudomonas aeruginosa isolates resistant to carbapenems. J Infect Dev Count 11:935\u2013943","journal-title":"J Infect Dev Count"},{"issue":"6","key":"2875_CR85","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/mdr.2017.0078","volume":"24","author":"M Rahman","year":"2018","unstructured":"Rahman M et al (2018) Prevalence and molecular characterization of new Delhi metallo-beta-lactamases in multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from India. Microb Drug Resist 24(6):792\u2013798","journal-title":"Microb Drug Resist"},{"issue":"5","key":"2875_CR86","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","volume":"11","author":"G Cornaglia","year":"2011","unstructured":"Cornaglia G, Giamarellou H, Rossolini GM (2011) Metallo-\u03b2-lactamases: a last frontier for \u03b2-lactams? Lancet Infect Dis 11(5):381\u2013393","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2875_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-017-1012-8","volume":"17","author":"AU Khan","year":"2017","unstructured":"Khan AU, Maryam L, Zarrilli R (2017) Structure, genetics and worldwide spread of New Delhi metallo-\u03b2-lactamase (NDM): a threat to public health. BMC Microbiol 17(1):1\u201312","journal-title":"BMC Microbiol"},{"issue":"6","key":"2875_CR88","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3201\/eid1906.121515","volume":"19","author":"JK Rasheed","year":"2013","unstructured":"Rasheed JK et al (2013) New Delhi metallo-\u03b2-lactamase\u2013producing enterobacteriaceae, United States. Emerg Infect Dis 19(6):870","journal-title":"Emerg Infect Dis"},{"key":"2875_CR89","doi-asserted-by":"publisher","first-page":"104588","DOI":"10.1016\/j.meegid.2020.104588","volume":"2020","author":"N Farhat","year":"2020","unstructured":"Farhat N, Khan AU (2020) Evolving trends of New Delhi Metallo-betalactamse (NDM) variants: a threat to antimicrobial resistance. Infect Genet Evol 2020:104588\u2013104589","journal-title":"Infect Genet Evol"},{"issue":"32","key":"2875_CR90","doi-asserted-by":"publisher","first-page":"12606","DOI":"10.1074\/jbc.RA118.003835","volume":"293","author":"Z Cheng","year":"2018","unstructured":"Cheng Z et al (2018) Evolution of New Delhi metallo-\u03b2-lactamase (NDM) in the clinic: effects of NDM mutations on stability, zinc affinity, and mono-zinc activity. J Biol Chem 293(32):12606\u201312618","journal-title":"J Biol Chem"},{"issue":"9","key":"2875_CR91","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","volume":"10","author":"KK Kumarasamy","year":"2010","unstructured":"Kumarasamy KK et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10(9):597\u2013602","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2875_CR92","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/jac\/dkt298","volume":"68","author":"APD Carvalho-Assef","year":"2013","unstructured":"Carvalho-Assef APD et al (2013) Isolation of NDM-producing Providencia rettgeri in Brazil. J Antimicrob Chemother 68(12):2956\u20132957","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2875_CR93","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1089\/mdr.2018.0240","volume":"25","author":"IR Silva","year":"2019","unstructured":"Silva IR et al (2019) Distribution of clinical NDM-1-producing Gram-negative bacteria in Brazil. Microb Drug Resist 25(3):394\u2013399","journal-title":"Microb Drug Resist"},{"key":"2875_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jgar.2019.09.009","volume":"19","author":"AML Scavuzzi","year":"2019","unstructured":"Scavuzzi AML et al (2019) Emergence of blaVIM-2, blaNDM-1, blaIMP-7 and blaGES-1 in blaKPC-2-harbouring Pseudomonas aeruginosa isolates in Brazil. J Glob Antimicrob Resist 19:181\u2013182","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"2875_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","unstructured":"Tsuji et al (2019) International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39(1):10\u201339","journal-title":"Pharmacotherapy"},{"issue":"10","key":"2875_CR96","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/jac\/dkw239","volume":"71","author":"M Falcone","year":"2016","unstructured":"Falcone M, Paterson D (2016) Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother 71(10):2713\u20132722","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2875_CR97","doi-asserted-by":"publisher","first-page":"e00846","DOI":"10.1128\/AAC.00846-21","volume":"65","author":"Khan","year":"2021","unstructured":"Khan et al (2021) Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother 65(11):e00846-e921","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2875_CR98","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","volume":"63","author":"Mikhail","year":"2019","unstructured":"Mikhail et al (2019) Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 63(8):e00779-e819","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2875_CR99","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","unstructured":"Kazmierczak et al (2019) In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 study). Int J Antimicrob Agents 53(2):177\u2013184","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"2875_CR100","doi-asserted-by":"publisher","first-page":"e01582","DOI":"10.1128\/AAC.01582-20","volume":"64","author":"Mushtaq","year":"2020","unstructured":"Mushtaq et al (2020) In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant gram-negative bacteria. Antimicrob Agents Chemother 64(12):e01582-e1620","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-02875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-022-02875-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-02875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:30:28Z","timestamp":1744201828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-022-02875-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s00284-022-02875-9","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"175"}}